Latigo Biotherapeutics secured $346 million in an IPO to fund a pipeline of non-opioid pain drug candidates, including an asset planned for pivotal testing. The company said it will apply proceeds toward advancing a “next-generation” pain therapy intended to improve upon existing pain management options without opioids. The financing also reflects ongoing capital interest in pain categories that remain commercially and clinically active, even as safety and long-term tolerability expectations tighten. Separately, BlossomHill Therapeutics also debuted on the Nasdaq with cash for cancer drugs aimed at addressing mutations not covered by existing therapies. For the sector, the dual IPO activity underscores renewed momentum in early-to-mid stage development where companies can articulate differentiated mechanisms and clear milestone-driven plans.